SCHEMBL287344

SCHEMBL287344

N#Cc1ccccc1COC(N)=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 1/20 0.57
KMT2A Q03164 2/20 0.53
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
TSHR P16473 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
FFAR1 O14842 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.47
KCNH2 Q12809 1/20 0.46
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
PLAU P00749 1/20 0.42
ALKBH1 Q13686 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5932420 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL30163264 0.84 ALDH1A1 (0.55) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL5932500 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL4618290 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL19765228 0.81 ALDH1A1 (0.54) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL29501710 0.81 SMN1; SMN2 (0.48) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL27594582 0.80 NPC1 (0.64) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL13069883 0.80 ALDH1A1 (0.53) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL6517065 0.79 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2ARAB9ANPC1
SCHEMBL28571348 0.79 ADRA1D (0.50) ALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11241435-B2 Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis THE GENERAL HOSPITAL CORPORATION (US) 2022-02-08 US claimed
US-12486289-B2 Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof THE BROAD INSTITUTE, INC. (US) 2025-12-02 US disclosed
US-12377037-B2 Cleavable comonomer strategy for accelerating removal of gel nail polish MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-08-05 US disclosed
WO-2025151874-A1 INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2025-07-17 WO disclosed
US-20250144227-A1 C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-05-08 US disclosed
US-20240423894-A1 CLEAVABLE COMONOMER STRATEGY FOR ACCELERATING REMOVAL OF GEL NAIL POLISH MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-12-26 US disclosed
US-12116364-B2 Heteroaryl compounds and uses thereof APRINOIA THERAPEUTICS INC. (CN) 2024-10-15 US disclosed
US-12083186-B2 Methods for assembling scavenging particles NANOTICS, LLC (US) 2024-09-10 US disclosed
US-20240269319-A1 METHODS FOR ASSEMBLING SCAVENGING PARTICLES NANOTICS, LLC 2024-08-15 US disclosed
US-20240228475-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE CELGENE CORPORATION 2024-07-11 US disclosed
WO-2008048714-A2 BIRADICAL POLARIZING AGENTS FOR DYNAMIC NUCLEAR POLARIZATION MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2008-04-24 WO disclosed
WO-2007117639-A9 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF HARVARD COLLEGE (US) 2008-04-17 WO disclosed
WO-2008028057-A2 SHIKIMIC ACID-DERIVED COMPOUNDS FOR INHIBITION AND DETECTION OF AURORA A-ASSOCIATED TUMORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-03-06 WO disclosed
EP-1863800-A2 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF The President and Fellows of Harvard College (US) 2007-12-12 EP disclosed
WO-2007008226-A9 PALLADIUM-CATALYZED CARBON-CARBON BOND FORMING REACTIONS HARVARD COLLEGE (US) 2007-05-24 WO disclosed
WO-2007056188-A1 SYNTHESIS OF INHIBITORS OF FTSZ PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-05-18 WO disclosed
EP-1753713-A2 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF The President and Fellows of Harvard College (US) 2007-02-21 EP disclosed
WO-2007013965-A2 SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2007-02-01 WO disclosed
WO-2006102097-A2 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2006-09-28 WO disclosed
WO-2005112945-A2 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12377037-B2 Cleavable comonomer strategy for accelerating removal of gel nail polish PRKDC, POLR1C, PIK3C3 ALDH1A1 2906/4885KDM4E 962/4885KMT2A 1221/4885
US-20240423894-A1 CLEAVABLE COMONOMER STRATEGY FOR ACCELERATING REMOVAL OF GEL NAIL POLISH PRKDC, POLR1C, NACA ALDH1A1 2928/4885KDM4E 1542/4885KMT2A 1526/4885
US-20250144227-A1 C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF UGT2B17, ABCB4, IL17A ALDH1A1 2383/4885KDM4E 1953/4885KMT2A 2024/4885
US-12486289-B2 Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof GSK3A, GSK3B, PYGB ALDH1A1 2505/4885KDM4E 2430/4885KMT2A 1091/4885
US-20240228475-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AQP1, AQP3, ADH1C ALDH1A1 749/4885KDM4E 1442/4885KMT2A 834/4885
US-12116364-B2 Heteroaryl compounds and uses thereof MAPT, APP, SLCO1B3 ALDH1A1 1918/4885KDM4E 4822/4885KMT2A 4329/4885
US-11241435-B2 Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis SOST, SIK2, SIK1 ALDH1A1 4790/4885KDM4E 1613/4885KMT2A 1338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.